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iﬁcation of the cohort using the predictive parameters “cumu-
lated complication events avoided” (CCEA) and “life years
gained” was more effective to identify those patients with a high
real-life improvement of outcomes than using others. Clinical
parameters performed particularly poorly even if they were com-
bined. For example, for the sub-cohort selected using highest
potential for “CCEA” the life expectancy increased by 0.26 years
per patient, but decreased by 0.29 if stratiﬁed by the risk factor
HbA1c > 7.5%. CONCLUSIONS: Individualised Predictive
Disease Modeling is a valuable strategy to identify patients with
the highest potential to avoid diabetes related complications.
This powerful strategy should be used to improve the effective-
ness and efﬁciency of DMPs for D.m.
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OBJECTIVES: To compare health care service utilization and
medication adherence in an elderly (age ≥ 65 years) population
newly starting thiazolidinedione therapy with patients starting
insulin or other oral antidiabetic medications in the same period.
METHODS: This was a retrospective data analysis using a
Medicare HMO database. We compared adherence, health care
service utilitzation, and cost impact of starting thiazolidinediones
for 12 months after initiation of therapy. A total of 165 patients
starting thiazolidinedione therapy between July 1999 and
December 2001 were compared with patients starting insulin (n
= 82) and other oral antidiabetic medication (n = 288). Propen-
sity scores were created by using variables from a comprehen-
sive health status assessment and health care claims data in the
year prior to beginning new antidiabetic medication and utilized
in multivariate analyses examining predictors of health care costs
and diabetes medication adherence in the year following start of
therapy. RESULTS: Patients starting thiazolidinedione therapy
had 56% higher medication adherence than did patients starting
insulin (P < 0.01) and had adherence comparable with that in
patients starting other oral antidiabetic medications (after con-
founder adjustment). There were no health care cost differences
between patients starting either drug therapy. CONCLUSIONS:
The introduction of thiazolidinedione therapy in an elderly type
2 diabetic population was associated with improved adherence
compared with insulin and with no increases in health care costs.
The usefulness of propensity scores in the bias reduction and bal-
anced sample selection while determining outcomes associated
with introduction of new pharmacotherapies is highlighted
through these ﬁndings.
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OBJECTIVE: Patient preferences are crucial in treatment deci-
sion-making when several equally efﬁcacious alternative treat-
ments are available. The objective of this study was to investi-
gate the principal drivers of treatment preference among indi-
viduals with type-2 diabetes. METHODS: We conducted 11
focus groups with 84 adults with type-2 diabetes supplemented
with treatment preference driver checklists. RESULTS: The ﬁrst
5 focus groups yielded 10 drivers of treatment preference. The
second 6 focus groups ranked the importance of the 10 drivers
among 100 points. The principal driver of treatment preference
was medication effectiveness with an average score of 36.2 out
of 100. The next two highly-rated drivers were treatment ﬂexi-
bility and physician recommendation (9.5 and 9.4, respectively),
followed by quality of life impacts and correct dosing (7.5 each),
ﬁnancial costs (7.3), treatment convenience (6.4), physical side
effects (6.3), emotional side effects (6.0), and treatment tolera-
bility (3.8). A full 62% of participants chose 5 or more drivers,
while only 12% chose one or two drivers. We then asked par-
ticipants to assume medication effectiveness was perfect and to
reallocate the 100 points among the remaining 9 drivers. In this
round, the principal driver of treatment preference was physical
side effects (17.4). The next most highly-rated drivers were ﬁnan-
cial costs and physician recommendation (12.9 and 12.2, respec-
tively), followed by correct dosing (11.1), treatment ﬂexibility
(10.9), quality of life impacts (10.1), treatment convenience
(9.4), emotional side effects (8.5), and treatment tolerability
(7.3). Only 8% of participants chose one or two drivers, 
while 38% chose 8 or more drivers. CONCLUSIONS: Great
variability exists in the drivers of treatment preference among
individuals with type-2 diabetes. Group averages mask tremen-
dous inter-individual variability in the importance of drivers 
and their relative rank. These ﬁndings underscore the need for
continued methodological work on the concept of treatment
preference.
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OBJECTIVE: Evaluate direct health care costs associated with
olanzapine and risperidone treatment for patients with schizo-
phrenia. METHODS: Using the North Carolina Medicaid
Claims database, patients diagnosed with schizophrenia (ICD9-
CM: 295) were assigned to olanzapine or risperidone cohort 
on the basis of which drug was received ﬁrst. Medication,
medical service and total health care costs were examined 
for schizophrenia-related, mental health related, and all-cause
services using multivariate models controlling for possible 
confounding factors including demographics, types of schizo-
phrenia, co-morbidities, and prior use of medications and
medical services. RESULTS: A total of 498 patients (286 olan-
zapine and 212 risperidone) were identiﬁed with available data
for three-month prior and eighteen-month after antipsychotic
treatment. During 18-month treatment, olanzapine patients
incurred signiﬁcantly higher drug expenditures (+$1235, p <
0.0001) than risperidone patients. Patients on olanzapine,
however, had signiﬁcantly lower medical service costs (-$3212,
p = 0.02) than risperidone patients, leading to no statistical 
difference in total health care costs between the two groups 
(-$1976 lower for olanzapine, p = 0.16). The ﬁndings are con-
sistent with the schizophrenia-related and mental health-related
cost models. Additionally, age, race, type of schizophrenia, 
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co-morbidities, and prior use of inpatient services were also
found to impact treatment costs. CONCLUSIONS: This study
ﬁnds that compared to risperidone, olanzapine is associated with
increased drug expenditures but reduced medical service costs.
Although total costs are similar, results suggest that schizophre-
nia patients might beneﬁt from olanzapine due to reduced
medical service use.
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OBJECTIVES: Investigate the impact of open access to atypical
antipsychotics on the cost of treating patients with severe mental
disorders. METHODS: Monthly cost data were derived for two
cohorts of California Medicaid patients with severe mental
illness. The intervention cohort (N = 92,089) utilized services
over the 24-months spanning the repeal of prior authorization
in October 1997. The control cohort (N = 75,551) used services
spanning October 1995. Multivariate time trend models for 
each service category were estimated to test whether utilization
patterns were altered after open access. RESULTS: The unad-
justed rate of growth for each type of service in the control
cohort was (-0.8% ~ +1.8%) compared to (0.0% ~ +3.5%) for
the intervention cohort. The multivariate time trend models for
all services found that total cost and long term care use increased
in the ﬁrst 2-months after open access by 4% and 3% respec-
tively, but consistently decreased in the next 10 months and 8
months, respectively. The estimated total cost savings from 
these changes in utilization patterns was $145.50 per patient 
per month over the 12-month period following open access.
CONCLUSIONS: These results suggest that policy analysts 
must be careful when evaluating open access to atypical antipsy-
chotics since short-term and long-term impacts on cost may
differ.
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Methylphenidate (MPH) has been shown to be an effective 
and cost-effective treatment for children and adolescents with
attention-deﬁcit/hyperactivity disorder (ADHD). Given their
short duration of action, MPH immediate-release (MPH-IR) for-
mulations require multiple daily dosing. Studies have reported
noncompliance rates of 20–65%. OBJECTIVE: To evaluate,
from the perspective of the UK NHS, the cost-effectiveness of
MPH-OROS, a novel once-a-day formulation. METHODS: A
meta-analysis was performed to synthesize data on clinical efﬁ-
cacy from three randomized clinical trials, comparing MPH-
OROS o.a.d., MPH-IR t.i.d., and placebo (Caro 2003). Results
were combined with unit cost data (BNF 2003, PSSRU 2003),
resource utilization estimates (NHS perspective), and assump-
tions on treatment compliance (systematic review, Claxton et al.
2001). Data were used to populate a decision tree model adapt-
ing and extending the CCOHTA analysis (1998) of ADHD ther-
apies. RESULTS: MPH-OROS and MPH-IR were signiﬁcantly
more efﬁcacious than placebo, in both community teacher and
parent ratings of inattention/overactivity (IOWA Conners I/O
scale; primary trial endpoint). For teacher ratings, standardized
mean differences (SMD, random effects model) compared to
placebo were 1.32 (1.09–1.55, 95% CI, for MPH-OROS) and
1.19 (1.00–1.38 for MPH-IR); effect sizes reported by parents
were generally higher and better for MPH-OROS compared to
MPH-IR. Assuming 79% compliance with MPH-OROS o.a.d.
and 65% with MPH-IR t.i.d. over one year, the incremental cost
of MPH-OROS per SMD (teacher ratings) was £1345 (for MPH-
IR: £1120); for parent ratings, MPH-OROS exhibited extended
dominance over MPH-IR. Comprehensive sensitivity analyses
were performed. For MPH-IR compliance rates below 57%,
MPH-OROS dominated (in an extended sense) also in teacher
ratings. CONCLUSION: These data indicate that MPH-OROS
may be more effective than MPH-IR t.i.d. in daily practice. They
suggest an acceptable incremental cost-effectiveness ratio of
MPH-OROS, with extended dominance over MPH-IR under a
broad range of assumptions. Real world data will have to
conﬁrm these estimates.
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OBJECTIVES: Attention-Deﬁcit/Hyperactivity Disorder
(ADHD) is a behavior disorder, originating in childhood, with
broad impairment in academic performance, social functioning,
and quality of life. Limited research on ADHD health state util-
ities has been previously reported using parent ratings. The
purpose of this study was to use standard gamble (SG) utility
valuation methodology to assess ADHD health states in a Euro-
pean sample of children diagnosed with ADHD. METHODS:
The study was conducted in August 2003 in London, England.
Parents of children diagnosed with ADHD completed the feeling
thermometer and SG utility interviews, in which they rated their
child’s current health and 14 hypothetical health states (e.g.,
untreated ADHD, short- and long-acting stimulant treatment,
and atomoxetine treatment [a new non-stimulant]). The hypo-
thetical health states were developed based on published litera-
ture, clinical trial data, and opinion of clinical experts. Parents
reported children’s symptoms using the 18-item ADHD-RS.
RESULTS: Participants were 83 parents of children diagnosed
with ADHD. The sample mean ADHD-RS total score was 37.
Raw and adjusted SG ratings were presented (the latter re-scales
the ratings as some parents were unable to take part in the hypo-
thetical gamble involving death). The mean parent raw and
adjusted SG ratings of their child’s current health state were 0.72
and 0.91, respectively. Raw and adjusted SG ratings of hypo-
thetical health states ranged from 0.63–0.90 and 0.88–0.96,
respectively. Parents’ responses to the hypothetical health states
using the feeling thermometer (range 0–100) were lower overall
(26–87) when compared to the SG scores, with parents’ rating
their own child’s current health state at 57. CONCLUSION: SG
rating scores can be obtained for children who have been diag-
nosed with ADHD by using their parents as proxies. Moreover,
parents are able to distinguish and evaluate different hypotheti-
cal ADHD health states by assigning unique values to the sce-
narios presented to them.
